Clinical data
Pronunciation mə-RO-pi-tant
Trade names Cerenia
AHFS/ International Drug Names
Routes of
By mouth (tablets) (only dogs); SQ, IV (dogs and cats)
ATCvet code QA04AD90 (WHO)
Legal status
Legal status
  • ℞ (Prescription only)
Synonyms (2S,3S)-2-Benzhydryl-N-(5-tert-butyl-2-methoxybenzyl) quinuclidin-3-amine
CAS Number 147116-67-4
PubChem (CID) 23724948
ChemSpider 176804 YesY
Chemical and physical data
Formula C32H40N2O
Molar mass 468.67 g/mol
3D model (Jmol) Interactive image

Maropitant (INN,[1]:254–5 trade name Cerenia sər-EEN-i-uh in the U.S. and other countries), used as maropitant citrate (USAN), is a neurokinin (NK1) receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007 for use in dogs,[2][3] and more recently has also been approved for use in cats.[4]

Maropitant also has anti-nociceptive (analgesic) properties. In a 2012 study, parenteral maropitant decreased the minimum alveolar concentration (MAC) of sevoflurane in a pain-response model. Epidural administration had no effect. It has also been shown to decrease the MAC of sevoflurane in a cat spay and dog spay model. Whether it has analgesic properties in awake animals remains to be proven, but anecdotal evidence indicates that it is being used for analgesia by many veterinarians.

See also


This article is issued from Wikipedia - version of the 11/17/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.